Skip to main content
SpringerLink
Log in

Economic evaluation and survival analysis of immunoglobulin adsorption in patients with idiopathic dilated cardiomyopathy

  • Original Papers
  • Published:
The European Journal of Health Economics, formerly: HEPAC Aims and scope Submit manuscript

Abstract

Idiopathic dilated cardiomyopathy (DCM) is a life-threatening heart disease and a major reason for heart transplantations. The medical efficacy of immunoadsorption (IA) for DCM patients has been demonstrated in initial clinical studies. This prospective matched-case control study examined 5-year survival rates, direct medical costs, and cost-effectiveness in Germany (n=34) from a health-care system perspective. In a cost-effectiveness analysis costs per life year gained were calculated. Patients treated with IA showed a greater survival rate: 5-year survival rate in the intervention group was 82% vs. 41% in controls. Log rank statistics after Kaplan-Meier analysis of cumulated survival probability were highly significant. Initial intervention costs for IA were found to be €28,400 per patient treated. Direct medical costs for a 5-year follow-up were €128,600 per patient treated with IA and €75,500 in controls. Considering only the actual survival time we calculated annual treatment costs of €24,900 in the IA group and €28,900 in controls. The cost-effectiveness ratio expressed in costs per life year gained was €34,400. This is the first controlled study to perform 5-year survival analysis and economic evaluation of this new emerging technology for patients with DCM. Although high initial treatment costs for IA are incurred, the significantly better survival rates lead to reasonable costs per live year gained.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1.

Similar content being viewed by others

References

  1. Bland JM, Altman DG (1998) Survival probabilities (the Kaplan-Meier method). BMJ 317:1572

    CAS  PubMed  Google Scholar 

  2. CCOHTA (1996) A guidance document for the costing process. CCOHTA: Ottawa

  3. CCOHTA (1997) Guidelines for economic evaluation of pharmaceuticals: Canada, 2nd edn. CCOHTA: Ottawa

  4. Dec GW, Fuster V (1994) Idiopathic dilated cardiomyopathy—review article. N Engl J Med 331:1564–1575

    CAS  PubMed  Google Scholar 

  5. Drummond MF, O'Brien BJ, Stoddart GL, Torrance GW (1997) Methods for the economic evaluation of health care programmes. Oxford University Press: Oxford

    Google Scholar 

  6. Feldman AM, McNamara DM (2000) Myocarditis. N Engl J Med 343:1388–1398

    Article  CAS  PubMed  Google Scholar 

  7. Felix SB, Staudt A, Dorffel WV, Stangl V, Merkel K, Pohl M, Docke WD, Morgera S, Neumayer HH, Wernecke KD, Wallukat G, Stangl K, Baumann G (2000) Hemodynamic effects of immunoadsorption and subsequent immunoglobulin substitution in dilated cardiomyopathy: three-month results from a randomized study. J Am Coll Cardiol 35:1590–1598

    Article  CAS  PubMed  Google Scholar 

  8. Gold MR, Siegel JE, Russell LB, Weinstein MC (1996) Cost-effectiveness in health and medicine. Oxford University Press: Oxford

    Google Scholar 

  9. Gruppe HK (1999) Empfehlungen zur gesundheitsökonomischen Evaluation—revidierte Fassung des Hannoveraner Konsens. Gesundheitsokon Qualitatsmanage 4:A62–A65

    Google Scholar 

  10. Hessel FP, Kohlmann T, Krauth C, Nowy R, Seitz R, Siebert U, Wasem J (1999) Ökonomische Evaluation in der Rehabiliation: Prinzipien und Empfehlungen für die Leistungserfassung. DRV-Schriften 16:103–246

  11. Hirth RA, Chernow ME, Miller E, Fendrick AM, Weissert WG (2000) Willingness to pay for a quality adjusted life year: In search of a standard. Med Decis Making 20:332–342

    CAS  PubMed  Google Scholar 

  12. Hobbs FD, Kenkre, JE, Roalfe AK, Davis RC, Hare R, Davis MK (2002) Impact of heart failure and left ventricular systolic dysfunction on quality of life: a cross-sectional study comparing common chronic cardiac and medical disorders and a representative adult population. Eur Heart J 23:1867–1876

    Article  CAS  PubMed  Google Scholar 

  13. Hosenpud JD, Bennett LE, Keck BM, Fiol B, Novick RJ (1997) The registry of the International Society for Heart and Lung Transplantation. Fourteenth official report 1997. J Heart Lung Transplant 16:691–712

    CAS  PubMed  Google Scholar 

  14. Jünger J, Schellberg D, Kraemer S, Haunstetter A, Zugck C, Herzog W, Haass M (2002) Health related quality of life in patients with congestive heart failure: comparison with other chronic diseases and relation to functional variables. Heart 87:235–241

    Article  PubMed  Google Scholar 

  15. Mann DL (2001) Autoimmunity, immunoglobulin adsorption and dilated cardiomyopathy: has the time come for randomized clinical trials? J Am Coll Cardiol 38:184–186

    Article  CAS  PubMed  Google Scholar 

  16. Muller J, Wallukat G, Dandel M, Bieda H, Brandes K, Spiegelsberger S, Nissen E, Kunze R, Hetzer R (2000) Immunoglobulin adsorption in patients with idiopathic dilated cardiomyopathy. Circulation 101:385–391

    CAS  PubMed  Google Scholar 

  17. Richardson P, McKenna W, Bristow M, Maisch B, Mautner B, O'Connell J, Olsen E, Thiene G, Goodwin J, Gyarfas I, Martin I, Nordet P (1996) Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of Cardiomyopathies. Circulation 93:841–842

    PubMed  Google Scholar 

  18. Schimke I, Muller J, Priem F, Kruse I, Schon B, Stein J, Kunze R, Wallukat G, Hetzer R (2001) Decreased oxidative stress in patients with idiopathic dilated cardiomyopathy one year after immunoglobulin adsorption. J Am Coll Cardiol 38:178–183

    Article  CAS  PubMed  Google Scholar 

  19. Tamburro P, Wilber D (1992) Sudden death in idiopathic dilated cardiomyopathy. Am Heart J 124:1035–1045

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This study was supported in part by PlasmaSelect AG, Teterow, Germany.

Author information

Authors and Affiliations

  1. University of Duisburg-Essen, Germany

    Franz P. Hessel & Jürgen Wasem

  2. University of Greifswald, Germany

    Christoph Wegner

  3. German Heart Institute Berlin, Germany

    Johannes Müller

  4. Clinic for Internal Medicine Offenbach, Germany

    Christina Glaveris

  5. Alfried Krupp von Bohlen und Halbach Foundation, Institute for Health Care Management, Faculty of Economics, University of Duisburg-Essen, Universitätsstrasse 2, 45117, Essen, Germany

    Franz P. Hessel

Authors
  1. Franz P. Hessel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christoph Wegner
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Johannes Müller
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Christina Glaveris
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jürgen Wasem
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Franz P. Hessel.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hessel, F.P., Wegner, C., Müller, J. et al. Economic evaluation and survival analysis of immunoglobulin adsorption in patients with idiopathic dilated cardiomyopathy. HEPAC 5, 58–63 (2004). https://doi.org/10.1007/s10198-003-0202-5

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10198-003-0202-5

Keywords

Search

Navigation